Specifically, GACAT3 is considered to be a valuable target for therapeutic intervention in GC, CRC, HCC, breast cancer, bladder cancer, NSCLC, and glioma (Pan et al., 2019). This evidence concerns the gene GACAT3 and central nervous system cancer.